Barbara Gayle Duncan, Chief Financial Officer at INTERCEPT PHARMACEUTICALS INC (ICPT), sold 1,000 shares at $154.45 ($156K) on 2015-01-02, disclosed to the SEC on 2015-01-05.
Scheduled sale ($156k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $154.45 | 500 | $77K | 49.4% |
| 2 | $158.35 | 500 | $79K | 50.6% |
| Total | $156.40 avg | 1,000 | $156K | 100% |
| Filing → |
| JNCE | SELL | 2018-01-29 | $100K | — | Filing → |
| GNMX | BUY | 2017-10-18 | $150K | — | Filing → |
| ICPT | SELL | 2016-10-05 | $24K | — | Filing → |